Log in

NASDAQ:ORGO - Organogenesis Stock Price, Forecast & News

-0.18 (-5.08 %)
(As of 03/29/2020 05:57 AM ET)
Today's Range
Now: $3.36
50-Day Range
MA: $4.04
52-Week Range
Now: $3.36
Volume43,777 shs
Average Volume163,056 shs
Market Capitalization$354.01 million
P/E RatioN/A
Dividend YieldN/A
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
Read More

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ORGO



Sales & Book Value

Annual Sales$260.98 million
Book Value$0.59 per share


Net Income$-40,450,000.00


Market Cap$354.01 million
Next Earnings Date5/8/2020 (Estimated)
OptionableNot Optionable

Receive ORGO News and Ratings via Email

Sign-up to receive the latest news and ratings for ORGO and its competitors with MarketBeat's FREE daily newsletter.

Organogenesis (NASDAQ:ORGO) Frequently Asked Questions

How has Organogenesis' stock been impacted by COVID-19 (Coronavirus)?

Organogenesis' stock was trading at $2.98 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ORGO stock has increased by 12.8% and is now trading at $3.36. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Organogenesis?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Organogenesis in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Organogenesis.

When is Organogenesis' next earnings date?

Organogenesis is scheduled to release its next quarterly earnings announcement on Friday, May 8th 2020. View our earnings forecast for Organogenesis.

How were Organogenesis' earnings last quarter?

Organogenesis Holdings Inc (NASDAQ:ORGO) issued its quarterly earnings data on Monday, March, 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.05. The firm earned $74.65 million during the quarter. Organogenesis had a negative return on equity of 126.41% and a negative net margin of 15.50%. View Organogenesis' earnings history.

What guidance has Organogenesis issued on next quarter's earnings?

Organogenesis updated its FY 2020 After-Hours earnings guidance on Monday, March, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $273-277 million, compared to the consensus revenue estimate of $271.38 million.

What price target have analysts set for ORGO?

5 analysts have issued 12 month target prices for Organogenesis' stock. Their forecasts range from $8.00 to $11.00. On average, they expect Organogenesis' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 197.6% from the stock's current price. View analysts' price targets for Organogenesis.

Has Organogenesis been receiving favorable news coverage?

Headlines about ORGO stock have trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Organogenesis earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutOrganogenesis.

Are investors shorting Organogenesis?

Organogenesis saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 169,300 shares, an increase of 43.7% from the February 27th total of 117,800 shares. Based on an average daily volume of 184,300 shares, the days-to-cover ratio is presently 0.9 days. Currently, 1.6% of the shares of the stock are short sold. View Organogenesis' Current Options Chain.

Who are some of Organogenesis' key competitors?

What other stocks do shareholders of Organogenesis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Organogenesis investors own include Opko Health (OPK), Genocea Biosciences (GNCA), Strongbridge Biopharma (SBBP), vTv Therapeutics (VTVT), Nokia Oyj (NOK), Gilead Sciences (GILD), OrganiGram (OGI), Ovid Therapeutics (OVID), Stitch Fix (SFIX) and Cloudera (CLDR).

Who are Organogenesis' key executives?

Organogenesis' management team includes the following people:
  • Mr. Gary S. Gillheeney Sr., Pres, CEO & Director (Age 64)
  • Mr. Timothy M. Cunningham, Chief Financial Officer (Age 57)
  • Mr. Patrick Bilbo, Chief Operating Officer (Age 57)
  • Ms. Lori H. Freedman, VP & Gen. Counsel (Age 52)
  • Angelyn Lowe, Director of Corp. Communications

What is Organogenesis' stock symbol?

Organogenesis trades on the NASDAQ under the ticker symbol "ORGO."

Who are Organogenesis' major shareholders?

Organogenesis' stock is owned by many different institutional and retail investors. Top institutional shareholders include Hussman Strategic Advisors Inc. (0.21%), Geode Capital Management LLC (0.21%), State Street Corp (0.17%), Bank of Montreal Can (0.12%), Charles Schwab Investment Management Inc. (0.12%) and Monashee Investment Management LLC (0.12%). Company insiders that own Organogenesis stock include Alan A Ades, Arthur S Leibowitz, Avista Capital Managing Member and Michael W Katz. View institutional ownership trends for Organogenesis.

Which major investors are selling Organogenesis stock?

ORGO stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund. View insider buying and selling activity for Organogenesis.

Which major investors are buying Organogenesis stock?

ORGO stock was bought by a variety of institutional investors in the last quarter, including Hussman Strategic Advisors Inc., Bank of Montreal Can, Monashee Investment Management LLC, K2 Principal Fund L.P., Charles Schwab Investment Management Inc., Guild Investment Management Inc., State Street Corp, and Private Advisors LLC. Company insiders that have bought Organogenesis stock in the last two years include Alan A Ades, Arthur S Leibowitz, Avista Capital Managing Member, and Michael W Katz. View insider buying and selling activity for Organogenesis.

How do I buy shares of Organogenesis?

Shares of ORGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Organogenesis' stock price today?

One share of ORGO stock can currently be purchased for approximately $3.36.

How big of a company is Organogenesis?

Organogenesis has a market capitalization of $354.01 million and generates $260.98 million in revenue each year. The company earns $-40,450,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis. Organogenesis employs 700 workers across the globe. View additional information about Organogenesis.

What is Organogenesis' official website?

The official website for Organogenesis is http://organogenesis.com/.

How can I contact Organogenesis?

Organogenesis' mailing address is 85 Dan Road, Canton MA, 02021. The company can be reached via phone at 781-575-0775 or via email at [email protected]

MarketBeat Community Rating for Organogenesis (NASDAQ ORGO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  50 (Thanks for Voting!)
Underperform Votes:  50 (Thanks for Voting!)
Total Votes:  100
MarketBeat's community ratings are surveys of what our community members think about Organogenesis and other stocks. Vote "Outperform" if you believe ORGO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORGO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Featured Article: Growth and Income Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel